SOF LED | SOF DACLA | P value | ||
N=51 | N=77 | |||
Uric acid before ttt | Mean±SD | 4.9±1.2 | 4.6±1.08 | 0.1135 |
Median | 5 | 4.1 | ||
IQR | 4–6 | 4–5 | ||
Uric acid end of ttt | Mean±SD | 6.1±3.1 | 5.6±2.6 | 0.100 |
Median | 5 | 4.8 | ||
IQR | 4.5–6 | 4–5.5 | ||
ALT before ttt | Median | 53 | 58 | 0.170 |
IQR | 47–65 | 47–74 | ||
ALT end of ttt | Median | 28 | 28 | 0.119 |
IQR | 25–29 | 26–30 | ||
AST before ttt | Median | 59 | 67 | 0.053 |
IQR | 49–75 | 53.5–86 | ||
AST end of ttt | Median | 31 | 34 | 0.055 |
IQR | 28–33 | 29.5–37.5 | ||
Creatinine before ttt | Mean±SD | 0.98±0.21 | 0.95±0.19 | 0.320 |
Median | 1 | 0.9 | ||
IQR | 0.8–1.1 | 0.8–1 | ||
Creatinine end of ttt | Mean±SD | 1.12±0.61 | 1.11±0.56 | 0.649 |
Median | 1 | 1 | ||
IQR | 0.9–1.1 | 0.9–1 | ||
Platelets before ttt | Median | 101 | 110 | 0.063 |
IQR | 87–123 | 95.5–126 | ||
Platelets end of ttt | Median | 104 | 115 | 0.093 |
IQR | 87–130 | 94–129 | ||
Bilirubin before ttt | Median | 1.1 | 1.2 | 0.982 |
IQR | 0.9–1.3 | 0.9–1.4 | ||
Bilirubin end of ttt | Median | 1.09 | 1.2 | 0.082 |
IQR | 0.9–1.2 | 0.9–1.35 | ||
Albumin before ttt | Median | 3.7 | 3.6 | 0.566 |
IQR | 3.5–4.2 | 3.4–3.8 | ||
Albumin end of ttt | Median | 3.7 | 3.6 | 0.256 |
IQR | 3.4–4.2 | 3.4–3.9 | ||
INR before ttt | Range | 1–1.8 | 1–1.7 | 0.096 |
Mean±SD | 1.2±0.2 | 1.3±0.2 | ||
INR end of ttt | Range | 1–1.7 | 1–1.6 | 0.078 |
Mean±SD | 1.2±0.3 | 1.2±0.2 |
Independent samples t-test for parametric quantitative data between the two groups.
Mann Whitney test for non-parametric quantitative data between the two groups.
Significant level at italics p value <0.05.
ALT, alanine transaminase; AST, aspartate transaminase; DACLA, daclatsvir; INR, international normalised ratio; LED, ledipasvir; SOF, sofosbuvir; ttt, treatment.